Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
March 1, 2022
March 1, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
March 1, 2022
March 1, 2022
Rachel Ford Hutman rachel@fordhutmanmedia.com 301.801.5540
Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer. The company combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer. For more information visit strataoncology.com.
In the news
Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium
Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards
Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%
Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer
Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%
Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit
Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors
Evaluation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab (pembro) Clinical Benefit in Patients (pts) with Advanced Solid Tumors